Literature DB >> 2178004

Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants.

E A Chiocca1, B B Choi, W Z Cai, N A DeLuca, P A Schaffer, M DiFiglia, X O Breakefield, R L Martuza.   

Abstract

Three mutants of herpes simplex virus type 1 (HSV-1) were used to deliver and express the Escherichia coli lacZ gene in cells of the rat central nervous system. Because the lacZ gene was inserted in place of the genes encoding one of the immediate-early viral proteins ICP0 or ICP4 or the early viral protein thymidine kinase, these mutants were compromised or defective in their ability to replicate. All mutant vectors exhibited reduced pathogenesis in animals as compared to the wild type HSV-1 strain KOS. In all cases lacZ was under the control of immediate-early or early viral promoters that are active in the early phase of infection. Expression of beta-galactosidase was observed in cortical neurons following stereotactic inoculation of mutant viruses into adult rat brains; distinct patterns of expression were observed with each mutant vector. Injection of the ICP0 mutant in the frontal cortex and caudate nucleus resulted in beta-galactosidase expression in a substantial number of cells around the inoculation site and at some distance from it for 14 days, with maximum expression after 3 days. The ICP0 vector appeared to have reached the ipsilateral and contralateral cingulate cortex by retrograde transport. Following inoculations of the ICP4 and thymidine kinase vectors into the same brain regions, only a few cells in areas immediately adjacent to the injection track expressed beta-galactosidase and they did so for only a few days. These herpes virus-derived vectors provide a means for the in situ delivery and expression of specific genes in neurons in the central nervous system with little adverse effect on animals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178004

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  27 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 4.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

5.  An enhanced packaging system for helper-dependent herpes simplex virus vectors.

Authors:  T A Stavropoulos; C A Strathdee
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.

Authors:  U Blömer; L Naldini; T Kafri; D Trono; I M Verma; F H Gage
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Approaches for stoichiometry and distance determination of nanometer bio-complex by dual-channel single molecule imaging.

Authors:  Hui Zhang; Dan Shu; Mark Browne; Peixuan Guo
Journal:  IEEE NIH Life Sci Syst Appl Workshop       Date:  2009-04-09

Review 8.  Gene Delivery in Neuro-Oncology.

Authors:  Karan Dixit; Priya Kumthekar
Journal:  Curr Oncol Rep       Date:  2017-09-02       Impact factor: 5.075

Review 9.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

10.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.